Short description
Aridis is a biopharmaceutical company focused on the development of novel, differentiated therapies for infectious diseases.
Description
Aridis Pharmaceuticals discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The company is utilizing its proprietary ʎPEXTM and MabIgX technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome infection and to rapidly manufacture monoclonal antibodies (mAbs) for the therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality.
Last funding
Nopepepe
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
San Jose, California, United States, North America
Founded on
January 1, 2003
Exited on
August 13, 2018
Went public on
August 13, 2018
Stock symbol
ARDS
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$7890 - 12340
Sign in for full access
Investors
Noway Youcantaccess, Noaccess, Blurry Noaccess
Sign in for full access
Founders
Eric Patzer, Vu L. Truong